GlassScriptPhysician profile
Michael Y Choi
NPI 1912181173
$6,691.23
in general payments reported to CMS, 2019-2025
23 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $98.65 · 2021: $287 · 2022: $551 · 2023: $4,092 · 2024: $416 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,285 · Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,285.00 |
| Food and Beverage | $1,578.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,285.00 | 2023 | Imbruvica |
| Abbvie INC. | $615.31 | 2022-2024 | Venclexta |
| Gilead Sciences, INC. | $556.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $480.88 | 2019-2025 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $410.11 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $361.06 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Verastem, INC. | $211.83 | 2019-2020 | |
| Foundation Medicine, INC. | $123.67 | 2023 | |
| Epizyme, INC. | $121.87 | 2021 | |
| Abbott Laboratories | $104.70 | 2022 | |
| Adc Therapeutics America, INC. | $94.16 | 2023 | |
| Beigene USA, INC. | $91.10 | 2022-2023 | Brukinsa |
| Genentech USA, INC. | $66.55 | 2021 | |
| Medexus Pharma, INC. | $51.24 | 2025 | Grafapex |
| Beone Medicines USA, INC. | $48.09 | 2025 | Brukinsa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $35.82 | 2022 | |
| Astrazeneca Uk Limited | $33.54 | 2023 | Calquence |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.